Lansoprazole: Package Insert and Label Information (Page 11 of 11)

PRINCIPAL DISPLAY PANEL – 15 mg

NDC 0378-6981-88

Lansoprazole
Delayed-Release Orally Disintegrating
Tablets
15 mg

Phenylketonurics: Contains phenylalanine (a component of aspartame) 3.37 mg per tablet.

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

Rx only 100 Unit-Dose Tablets (10 Cards x 10 Tablets)

Each tablet contains 15 mg of lansoprazole, USP as enteric-coated pellets.

Usual Dosage: See accompanying prescribing information.

Store at 20° to 25°C (68° to 77°F).

[See USP Controlled Room Temperature.]

Medication Guides may be obtained at Mylan.com/MedCenter or call 1-888-839-8993.

Keep this and all medication out of the reach of children.

Do not use if blisters are torn, broken or missing.

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Made in India

Code No.: MH/DRUGS/25/NKD/89

Mylan.com

MX:6981:100C:R5

PHARMACIST INSTRUCTIONS FOR THE PATIENT

Please inform patients of the following instructions for product use:

Lansoprazole delayed-release orally disintegrating tablets should not be chewed.

Lansoprazole delayed-release orally disintegrating tablets should be taken before eating.

Place the tablet on the tongue and allow it to disintegrate, with or without water, until the pellets can be swallowed.

Alternatively for children or other patients who have difficulty swallowing tablets, lansoprazole delayed-release orally disintegrating tablets can be delivered via oral syringe.

Place a 15 mg tablet in oral syringe and draw up approximately 4 mL of water.
Shake gently to allow for a quick dispersal.
After the tablet has dispersed, administer the contents within 15 minutes.
Refill the syringe with approximately 2 mL of water, shake gently and administer any remaining contents.

See accompanying prescribing information for nasogastric tube administration.

BLISTER OPENING INSTRUCTIONS

Carton Blister Opening Instructions
1.
Do not press blister pocket to open.
2.
Tear along the perforations to separate andremove one blister from the strip.
3.
Detach the triangular notch from the blister.
4.
Tear or Cut at notch to access the tablet.
5.
Remove the tablet from the opened blister.
Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg Carton Label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL – 30 mg

NDC 0378-6982-88

Lansoprazole
Delayed-Release Orally Disintegrating
Tablets
30 mg

Phenylketonurics: Contains phenylalanine (a component of aspartame) 6.74 mg per tablet.

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

Rx only 100 Unit-Dose Tablets (10 Cards x 10 Tablets)

Each tablet contains 30 mg of lansoprazole, USP as enteric-coated pellets.

Usual Dosage: See accompanying prescribing information.

Store at 20° to 25°C (68° to 77°F).

[See USP Controlled Room Temperature.]

Medication Guides may be obtained at Mylan.com/MedCenter or call 1-888-839-8993.

Keep this and all medication out of the reach of children.

Do not use if blisters are torn, broken or missing.

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Made in India

Code No.: MH/DRUGS/25/NKD/89

Mylan.com

MX:6982:100C:R5

PHARMACIST INSTRUCTIONS FOR THE PATIENT

Please inform patients of the following instructions for product use:

Lansoprazole delayed-release orally disintegrating tablets should not be chewed.

Lansoprazole delayed-release orally disintegrating tablets should be taken before eating.

Place the tablet on the tongue and allow it to disintegrate, with or without water, until the pellets can be swallowed.

Alternatively for children or other patients who have difficulty swallowing tablets, lansoprazole delayed-release orally disintegrating tablets can be delivered via oral syringe.

Place a 30 mg tablet in oral syringe and draw up approximately 10 mL of water.
Shake gently to allow for a quick dispersal.
After the tablet has dispersed, administer the contents within 15 minutes.
Refill the syringe with approximately 5 mL of water, shake gently and administer any remaining contents.

See accompanying prescribing information for nasogastric tube administration.

BLISTER OPENING INSTRUCTIONS

Carton Blister Opening Instructions
1.
Do not press blister pocket to open.
2.
Tear along the perforations to separate andremove one blister from the strip.
3.
Detach the triangular notch from the blister.
4.
Tear or Cut at notch to access the tablet.
5.
Remove the tablet from the opened blister.
Lansoprazole Delayed-Release Orally Disintegrating Tablets 30 mg Carton LabelLansoprazole Delayed-Release Orally Disintegrating Tablets 30 mg Carton Label
(click image for full-size original)
LANSOPRAZOLE lansoprazole tablet, orally disintegrating, delayed release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-6981
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LANSOPRAZOLE (LANSOPRAZOLE) LANSOPRAZOLE 15 mg
Inactive Ingredients
Ingredient Name Strength
ASPARTAME
CITRIC ACID MONOHYDRATE
CROSPOVIDONE
HYDROXYPROPYL CELLULOSE, UNSPECIFIED
MAGNESIUM CARBONATE
MAGNESIUM STEARATE
MANNITOL
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
MICROCRYSTALLINE CELLULOSE
POLYETHYLENE GLYCOL, UNSPECIFIED
POLYSORBATE 80
SODIUM BICARBONATE
SODIUM HYDROXIDE
SODIUM LAURYL SULFATE
SODIUM STARCH GLYCOLATE TYPE A POTATO
TALC
TRIETHYL CITRATE
FERRIC OXIDE YELLOW
STARCH, CORN
SUCROSE
Product Characteristics
Color YELLOW (pale yellow speckled) Score no score
Shape ROUND Size 11mm
Flavor STRAWBERRY Imprint Code M;LP1
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0378-6981-88 2 CARTON in 1 BOX contains a CARTON (0378-6981-85)
1 NDC:0378-6981-85 5 BLISTER PACK in 1 CARTON This package is contained within the BOX (0378-6981-88) and contains a BLISTER PACK (0378-6981-32)
1 NDC:0378-6981-32 10 TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE in 1 BLISTER PACK This package is contained within a CARTON (0378-6981-85) and a BOX (0378-6981-88)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA202396 11/29/2018
LANSOPRAZOLE lansoprazole tablet, orally disintegrating, delayed release
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-6982
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LANSOPRAZOLE (LANSOPRAZOLE) LANSOPRAZOLE 30 mg
Inactive Ingredients
Ingredient Name Strength
ASPARTAME
CITRIC ACID MONOHYDRATE
CROSPOVIDONE
HYDROXYPROPYL CELLULOSE, UNSPECIFIED
MAGNESIUM CARBONATE
MAGNESIUM STEARATE
MANNITOL
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
MICROCRYSTALLINE CELLULOSE
POLYETHYLENE GLYCOL, UNSPECIFIED
POLYSORBATE 80
SODIUM BICARBONATE
SODIUM HYDROXIDE
SODIUM LAURYL SULFATE
SODIUM STARCH GLYCOLATE TYPE A POTATO
TALC
TRIETHYL CITRATE
FERRIC OXIDE YELLOW
STARCH, CORN
SUCROSE
Product Characteristics
Color YELLOW (pale yellow speckled) Score no score
Shape ROUND Size 13mm
Flavor STRAWBERRY Imprint Code M;LP2
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0378-6982-88 2 CARTON in 1 BOX contains a CARTON (0378-6982-85)
1 NDC:0378-6982-85 5 BLISTER PACK in 1 CARTON This package is contained within the BOX (0378-6982-88) and contains a BLISTER PACK (0378-6982-32)
1 NDC:0378-6982-32 10 TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE in 1 BLISTER PACK This package is contained within a CARTON (0378-6982-85) and a BOX (0378-6982-88)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA202396 11/29/2018
Labeler — Mylan Pharmaceuticals Inc. (059295980)

Revised: 04/2022 Mylan Pharmaceuticals Inc.

DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2023. All Rights Reserved.